2024 AUA Annual Meeting Previews : Episode 3
Feature
Video
2024 AUA preview: Dr. Elterman on key research in BPH
Author(s):
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Video Player is loading.
In this video, Dean S. Elterman, MD, MSc, FRCSC, highlights 4 studies in benign prostatic hyperplasia (BPH) that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Elterman is a urologist at the University of Toronto in Canada.
Elterman previewed the following abstracts:
- MP46-02 (Roehrborn et al): The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study
- MP06-15 (Elliott et al): The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 4-year interim results
- MP46-04 (Cerrato et al): Rezum for BPH: results from a large retrospective multicenter study
- MP27-01 (Gilling et al): 24-Month Outcomes from the ZEST Pilot studies of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
